In order to understand the deemed importance and subsequent...

In order to understand the deemed importance and subsequent disappointment of the failed progesterone (Protect) clinical trial, note the agenda for Day One of the upcoming Traumatic Brain Injury conference:

8:15 - The Protect 111 Clinical Trial, is there a Path Forward
8:35 - A Global Trial of Progesterone in TBI: Outcomes and Lessons

Colonel Hack from the US Army Medical Research and Materiel Command will make a presentation focussed upon solving the problems evidenced in the 33+ Phase 111 clinical trials that have failed to show a positive outcome. Finally, the attendees may then be interested in the presentation by Larry Glass which will focus upon;

"a robust statistical methodology that offers the potential to manage Type I and II errors in a rigorous manner that enhances the ability to interpret Phase II results as well as assisting in the selection of clinically meaningful endpoints for pivotal/Phase III trials."

Last man standing with a plan for a successful Phase 111 trial.